Navigation Links
Depomed Announces Appointment of Vicente J. Anido, Jr., Ph.D. to Board of Directors, and Retirement of Directors Julian N. Stern and Craig R. Smith, M.D.

NEWARK, Calif., Feb. 11, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced the appointment of Vicente Anido, Jr. , Ph.D., 60, to the company's Board of Directors.  Dr. Anido is the former President and Chief Executive Officer of ISTA Pharmaceuticals, which was acquired by Bausch + Lomb Incorporated in June 2012. 

"We are thrilled to have Vince join our Board of Directors," said James Schoeneck , Depomed's President and CEO. "Vince's significant depth and breadth of experience in the specialty pharmaceutical industry will be invaluable to Depomed as we drive the commercial success of our products and create new opportunities for growth," Mr. Schoeneck added.

"I am excited to join Depomed's Board of Directors," said Dr. Anido. "The company's product portfolio, commercial organization and experienced management team are great assets, and I look forward to contributing to Depomed's growth and success."

Prior to joining ISTA Pharmaceuticals as President and CEO in 2000, Dr. Anido served as a general partner of Windamere Venture Partners.  From 1996 to 1999, Dr. Anido served as President and Chief Executive Officer of CombiChem, Inc., a drug discovery company.  From 1993 to 1996, Dr. Anido served as President of the Americas Region of Allergan, Inc., where he was responsible for Allergan's commercial operations for North and South America.  Prior to Allergan, Dr. Anido spent 17 years in management positions at Marion Laboratories and Marion Merrell Dow , Inc., including as Vice President, Business Management of Marion's U.S. Prescription Products Division.  Dr. Anido received a B.S. and a M.S. from West Virginia University and a Ph.D. from the University of Missouri, Kansas City.

Depomed also announced today the retirement of Julian N. Stern and Craig R. Smith , M.D. as directors of Depomed, effective upon the election of directors at the Company's 2013 Annual Meeting of Shareholders. 

"I would like to thank Julian and Craig for their years of service and commitment to Depomed and its shareholders," said Peter Staple , the Chairman of Depomed's Board of Directors. "They have been important contributors to Depomed's development and growth, and I know I speak for everyone at Depomed in expressing our great appreciation for their service and the opportunity to work with them," Mr. Staple added.

About Depomed

Depomed, Inc. is a specialty pharmaceutical company with three approved and marketed products. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults. Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is commercialized by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for extended release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website,

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to the company's anticipated future growth, and other risks detailed in the company's Securities and Exchange Commission filings, including the company's Annual Report on Form 10-K for the year ended December 31, 2011 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2012. The inclusion of forward-looking statements should not be regarded as a representation that any of the company's plans or objectives will be achieved. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

August J. Moretti
Depomed, Inc.

SOURCE Depomed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Depomed To Present At Oppenheimer 2012 Healthcare Conference
2. Depomed Reports Top Line Data for Phase 2 Study in Parkinsons Disease
3. Depomed To Present At Lazard 2012 Healthcare Conference
4. Depomed Reports Third Quarter Financial Results
5. Depomed To Report Third Quarter Fiscal Year 2012 Financial Results On Monday, November 5, 2012
6. Depomed To Present At UBS Global Life Sciences Conference
7. Depomed To Present At Morgan Stanley 2012 Healthcare Conference
8. Depomed To Present At Stifel Nicolaus 2012 Healthcare Conference
9. Depomed To Report Second Quarter Fiscal Year 2012 Financial Results On Thursday, August 2, 2012
10. Depomed To Present At JMP Securities 7th Annual Healthcare Conference
11. Depomed Announces Filing Of Shelf Registration To Replace Existing Shelf
Post Your Comments:
(Date:11/30/2015)... KIRKLAND, Wash. , Nov. 30, 2015 /PRNewswire/ ... of Post-Processing services, is pleased to announce a ... of medical imaging services. Building on its ISO-9001:2008 ... adopted and implemented comprehensive Core Lab protocols and ... wide variety of research activities.  Their Core Lab ...
(Date:11/30/2015)... 30, 2015 Mexico Healthcare and Life Sciences ... Report 2015 . --> Pharmaboardroom releases its new 98-page ... Latin America , a country of over 122 million ... of over 122 million people. --> It offers companies, ... life sciences insights into the second largest pharma and healthcare market ...
(Date:11/30/2015)... , November 30, 2015 Elbit ... the "Company") announced today that it was informed by InSightec ... Drug Safety (MFDS) has approved its Exablate Neuro system ... --> --> Insightec,s Exablate Neuro ... alternative that combines two technologies: Focused Ultrasound, which is ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... , ... The Foundation for Breast and Prostate Health (FBPH)—a ... with the award-winning creator and writer of Downton Abbey Julian Fellowes to host ... Union League of Philadelphia. , The benefit, titled “An Evening with Julian ...
(Date:11/30/2015)... PA (PRWEB) , ... November 30, 2015 , ... ... Specialty Ingredients (ASI) as their exclusive channel partner for the Nutraceutical Specialties products ... markets in the US, effective immediately. , “We are pleased to announce ...
(Date:11/30/2015)... ... November 30, 2015 , ... California-based i2i Systems, a ... today that Michigan-based Family Health Center (FHC) has selected i2iTracks as their population ... was awarded the largest Affordable Care Act grant for Federally Qualified Health Centers ...
(Date:11/30/2015)... PITTSBURGH, PA (PRWEB) , ... November 30, 2015 , ... ... quality of life in the womb. "My last baby had high blood pressure due ... way for mothers to protect their babies from noise pollution as well as radio ...
(Date:11/30/2015)... ... November 30, 2015 , ... In an interview with Andy ... a top ophthalmologist on Long Island’s east end. During the broadcast, entitled “Eyes: the ... and treatment of glaucoma and cataracts, and how a visit with his grandmother to ...
Breaking Medicine News(10 mins):